Sustained benefits seen with tralokinumab for atopic dermatitis
Click Here to Manage Email Alerts
Progressive improvement in atopic dermatitis symptoms was found with continued tralokinumab plus topical corticosteroids, according to a study.
“This study is a post-hoc analysis of the ECZTRA 3 clinical trials assessing the impact of tralokinumab over a 32-week treatment period. It included all patients who initiated tralokinumab, irrespective of the response at week 16,” Adriana Guana, MD, vice president of U.S. medical affairs for LEO Pharma, told Healio. “This study is most reflective of clinical practice because biologics are commonly used in combination with topical corticosteroids in the treatment of patients with moderate to severe atopic dermatitis.”
Patients in the study were randomly assigned 2:1 to receive subcutaneous tralokinumab (Adbry, LEO Pharma) 300 mg or placebo every 2 weeks with topical corticosteroids (TCS) as needed for 16 weeks. Patients who achieved IGA 0/1 or EASI75 were then again randomly assigned 1:1 to receive tralokinumab every 2 or 4 weeks with TCS as needed for an additional 16 weeks, while patients who did not have a clinical response received tralokinumab every 2 weeks plus TCS.
At week 32, 70.2% of those treated with tralokinumab achieved EASI75, with 50.4% achieving EASI90.
For those who originally achieved treatment success in the first 16 weeks and continued to receive tralokinumab every 2 weeks, 72.5% achieved EASI90 at week 32, while 63.8% of those who receive tralokinumab every 4 weeks achieved EASI90.
“What we saw was those patients who initiated tralokinumab, irrespective of the response at week 16 or the dose range, could go into the maintenance phase of every 2 or 4 weeks and, at week 32, tralokinumab provided that progressive and sustained improvement in the extent and severity of atopic dermatitis, but also in the patient reported outcomes of sleep disturbance and quality of life,” Guana said.
Patient reported outcomes including itch, sleep and quality of life showed improvement in the tralokinumab groups through week 32.
At week 16, 65.4% of those in the tralokinumab plus TCS group had improved DLQI scores, compared with 49.1% of those in the placebo plus TCS group. This was maintained through week 32, according to the study.
“This trial presents a more comprehensive assessment of the impact of tralokinumab in multiple domains beyond the primary and secondary endpoints,” Guana said.